OCREVUS® (ocrelizumab) for your patients with RMS and PPMS

Efficacy and safety in RMS and PPMS

Learn more about OCREVUS (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

OCREVUS® (ocrelizumab) Mechanism of action

Proposed mechanism of action (MOA) 3

The MOA is presumed to involve immunomodulation through binding to CD20-expressing B cells.

OCREVUS® (ocrelizumab) has more than five years of patient experience

Over 5 years of patient experience 2,3

OCREVUS has over 5 years of patient experience, including 2 years of controlled and 3+ years of open-label extension study.